Maryland Heights, MO, February 25, 2017 --(PR.com
)-- The global embolization in interventional oncology market is estimated to reach nearly USD 4.78 Billion in 2020, expanding at a CAGR of 16.9% from 2016 to 2020.
Browse Embolization in Interventional Oncology Market by Procedure Type (Bland Embolization, Radioembolization, Transarterial Chemoembolization) and Forecast 2016-2020 at https://www.ihealthcareanalyst.com/report/embolization-interventional-oncology-market/.
Therapeutic interventional oncology procedures such as embolization techniques aims to occlude the blood vessels feeding the tumor and thereby destroy it by means of ischemia. Embolization techniques are minimally invasive treatment, i.e. they may be delivered through the skin (in a percutaneous way) without the need for any skin incisions or other form of open surgery. Hence, most treatments are nowadays offered as day case or outpatient appointments and patients may enjoy rapid recovery and minimal pain and discomfort with low rates of complications. Bland embolization includes delivery of sub-millimeter microparticles through a catheter inserted in the groin and advanced into the liver under X-ray guidance to get access into the tumor vasculature. Selective internal radiation therapy (also known as SIRT or radioembolization) includes microspheres loaded with a radioactive isotope (Yttrium-90) are injected into the blood vessels feeding a tumor and deliver a lethal dose of radiation into the vessels feeding the tumor thereby causing cell death. Transarterial chemoembolization (TACE) includes delivery of intra-arterial chemotherapy to the liver through a catheter in combination with embolic material to produce ischemia. Drug eluting bead chemoembolization (DEB-TACE) includes delivery of microparticles that are themselves loaded with the chemotherapy agent – doxorubicin – and allow for prolonged elution into the tumor microvessels.
The global embolization in interventional oncology market report estimates the market size (Revenue USD million – 2013 to 2020) based on embolization procedure type (bland embolization, radioembolization, transarterial chemoembolization), by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and forecasts growth trends (CAGR% – 2016 to 2020). The global embolization in interventional oncology market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global embolization in interventional oncology market and profiled in this report include Blockade, Braile Biomedica, BTG International, CeloNova BioSciences, Inc., Cook Medical, Covidien, Depuy Synthes, Merit Medical Systems, Inc., Penumbra, Sequent Medical, Stryker, and Terumo.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/embolization-interventional-oncology-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043